Table 2

ETDs for semaglutide vs. placebo and liraglutide at week 12 (HbA1c, FPG, and body weight)

ETDsSemaglutideLiraglutide
0.1 mg0.2 mg0.4 mg0.8 mg0.8 mg E1.6 mg E1.2 mg1.8 mg
HbA1c, % (95% CI)
 vs. placebo−0.1 (−0.5, 0.3)−0.4* (−0.8, −0.0)−0.6*** (−1.0, −0.2)−1.0**** (−1.4, −0.6)−1.0**** (−1.3, −0.6)−1.2**** (−1.6, −0.8)−0.7 (−1.0, −0.4)−0.8 (−1.1, −0.6)
 vs. liraglutide 1.2 mg0.6 (0.3, 0.9)0.3 (−0.0, 0.6)0.1 (−0.2, 0.4)−0.3 (−0.6, 0.0)−0.3 (−0.6, 0.0)−0.5 (−0.8, −0.2)
 vs. liraglutide 1.8 mg0.8 (0.5, 1.0)0.4 (0.2, 0.7)0.2 (−0.1, 0.5)−0.1 (−0.4, 0.2)−0.1 (−0.4, 0.2)−0.4 (−0.6, −0.1)
FPG, mmol/L (95% CI)
 vs. placebo−0.1 (−1.0, −0.8)−0.6 (−1.5, −0.3)−1.2** (−2.1, −0.3)−2.0**** (−2.9, −1.0)−2.0**** (−2.9, −1.1)−2.1**** (−3.0, −1.2)−1.2 (−1.9, −0.5)−1.8 (−2.4, −1.1)
 vs. liraglutide 1.2 mg1.1 (0.5, 1.8)0.6 (−0.1, 1.3)0.0 (−0.7, 0.7)−0.8 (−1.5, −0.1)−0.8 (−1.5, −0.1)−0.9 (−1.6, −0.2)
 vs. liraglutide 1.8 mg1.7 (1.1, 2.4)1.1 (0.5, 1.8)0.6 (−0.1, 1.2)−0.2 (−0.9, 0.5)−0.2 (−0.9, 0.5)−0.3 (−1.0, 0.3)
Body weight, kg (95% CI)
 vs. placebo0.4 (−0.9, 1.7)0.1 (−1.2, 1.5)−0.8 (−2.1, 0.5)−2.2*** (−3.5, −0.9)−2.4**** (−3.7, −1.1)−3.6**** (−5.0, −2.3)−0.7 (−1.7, 0.3)−1.4 (−2.4, −0.4)
 vs. liraglutide 1.2 mg1.1 (0.1, 2.0)0.8 (−0.2, 1.8)−0.2 (−1.2, 0.8)−1.5 (−2.6, −0.5)−1.7 (−2.8, −0.7)−3.0 (−4.0, −2.0)
 vs. liraglutide 1.8 mg1.8 (0.8, 2.8)1.6 (0.6, 2.5)0.6 (−0.4, 1.5)−0.8 (−1.8, 0.2)−1.0 (−2.0, −0.0)−2.2 (−3.2, −1.3)
  • Estimates are from an ANOVA model with treatment, country, and previous treatment as fixed effects, and baseline value as the covariate; CIs for treatment differences vs. placebo are based on the Dunnett method (with 6 comparisons); CIs for treatment differences vs. liraglutide are not corrected for multiple testing.

  • *P < 0.05.

  • **P < 0.01.

  • ***P < 0.001.

  • ****P < 0.0001.